1Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med,2001,344(11),783-792.
3Forbes JF, Kennedy J, Pienkowski T, et al. BCIRG 007: randomized phase Ⅲ trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC) [J]. J Clin Oncol, 2006,24(Suppl) : 516.
4Minckwitz CV, Zielinski C, Maarteense E, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumah treatment: The TBP phase Ⅲ study (GBG 26/BIG 3-05)[J]. J Clin Oncol, 2008,26 (Suppl), 1025.
5Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J]. N Engl J Med, 2005,353(16):1659-1672.
6Romond EH, Perez EA. Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer [J].N Engl J Med,2005, 353 (16):1673-1684.
7Baselga J, Perez EA, Pienkowski T, et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2- positive early breast cancer [J]. Oncologist, 2006,11 (Suppl 1) :4-12.
8Slamon DJ, Romond EH, Perez EA. Advances in adjuvant therapy for breast cancer [J]. Clin Adv Hematol Oncol, 2006,4 (suppl 1) : 4 - 9.
9Geyer CE,Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J]. N Engl J Med,2006,355(26),2733-2743.
10Boccardo F, Kaufman B, Baselga J, et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU)[J]. J Clin Oncol, 2008,26 (Suppl) :1094.
二级参考文献20
1Thossen C. Trials of new combination of Herceptin in metastatic breast cancer [J]. Aaticancer Drugs, 2001, 12(Suppl 4): 19-25.
2Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER-2 immunophenotype and gene amplification [ J ]. J Clin Oncol, 2001, 19(10): 2587-2595.
3Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer [J]. Science,1989,244(4905) : 707-712.
4Lohrisch C, Piccart M. HER-2/neu as a predictive factor in breast cancer [J]. Clin Breast Cancer, 2001, 2(2): 129-135.
5Leyland Jones B. Trastuzumab: hopes and realities [J]. Lancet Oncol, 2002,3(3): 137-144.
6Pegram MD, Finn RS, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells [J]. Oncogene, 1997,15(5) : 537-547.
7Burstein HJ, Kuter I, Campos SM, Clinical activity of trastuzumab and vinorelbine in women with HER-2-overexpressing metastatic breast cancer [J]. J Clin Oncol, 2001, 19(10): 2722-2730.
8Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER-2 ( + ) metastatic breast cancer [J]. Oncologist, 2002,7(5):410-417.
9Bell R. Ongoing trials with trastuzumab in metastatic breast cancer[J]. Ann Oncol, 2001,12 (Suppl 1): 69-73.
10Pegram MD.Docetaxel and herceptin:fourdation for future strategies[J].Oncologist,2001,6 (Suppl 5):22-25.
1Veronesi U, Cascinellin, Marianin L, et al. Twenty-year follow up of a randomized study comparing breast-con- serving surgery with radical mastectomy for early breast cancer[J]. N Engl J Med,2002,347(16):1227-1232.
2Fisher B, Anderson S, Bryant J, et al. Twenty-year fol- low-up of a randomized trail comparing total mastecto- my,lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med,2002,347(16) : 1223-1241.
3van Dongen JA, Voogd AC, Fentiman IS, et al. Long- term results of a randomized trail comparing breast- conserving therapy with mastectomy .. European Organ- ization for Research and Treatment of Cancer 10801 trial[J]. J Natl Cancer Inst,2000,92(14) :1143-1150.
4Veronesi U, Paganelli G, Viale G, et aL A randomized comparison of sentinel-node biopsy with routine axilla- ry dissection in breast cancer [J]. N Engl J Med,2003, 349(6) :546-553.
5Prosnitz LR, Marks LB. Partial breast irradiation= a cautionary note[J]. Int J Radiat Oncol Biol Phys,2006, 65(2) :319-321.
6Goyal A, Mansel RE. Recent advances in sentinel lymph node biopsy for breast cancer[J]. Curt Opin On- col,2008,20(6) :621-626.
7Huang EH, Tucker Sir, Strom EA, et al. Postmastecto- my radiation improves local regional control and sur- vival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy [ J ]. J Clin Oncol, 2004, 22 ( 23 ) : 4691- 4699.
8Vogel CL, Cobleigh MA, Tripathy D, et al. First line hereeptin monotherapy in metastatic breast eancer[J]. Oneology,2001,61 Suppl 2:37 -42.
9Arpino G,Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family., molecular mechanism and clini- cal implications for endocrine therapy resistance[J]. Endocr Rev,2008,29(2) :217-233.
10Bonadonna G, Motiterni A, Zambetti M,et al. 30 years 'follow up of randomised studies of adjuvant CMF in operable breast cancer : cohort study [ J]. BMJ, 2005, 330(7485) :217.
